The effect of remimazolam tosilate on early cognitve function of elderly patients after sedation for gastrointestinal endoscopy

Effect of remimazolam tosilate combined with butorphanol tartrate on early cognitive function in elderly patients after sedation for GI endoscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042084

Enrollment

Unknown

Registered

2021-01-13

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delayed neurocognitive recovery

Interventions

R1:0.1mg/kg remimazolam tosilate

R2:0.2mg/kg remimazolam tosilate

P:propofol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged >= 60 years, no gender limit; 2. Patients receiving routine gastroscopy diagnosis and treatment; 3. The ASA score is I, II, and III; 4. 18g/m2 < BMI< 30kg/m2; 5. It is estimated that the gastroscope operation time will not exceed 30 minutes; 6. The modified Markov score is level I and level II; 7. Clearly understand and voluntarily participate in the study, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of mental illness, liver and kidney dysfunction, and cerebrovascular accident; 2. Patients who take psychiatric drugs such as Valium, anti-anxiety, alcoholism or drug abuse; 3. Have a history of heart or brain surgery; 4. Patients with language communication, vision or hearing impairment; 5. Those who are allergic or contraindicated to benzodiazepines, opioids, lidocaine and their drug components.

Design outcomes

Primary

Measure	Time frame
early cognitive function;	—

Countries

China

Contacts

Public ContactOuyang Wen

The Third Xiangya Hospital of Central South University

ouyangwen133@vip.sina.com+86 13974934441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026